Medical/Pharmaceuticals
Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
GAITHERSBURG, Md. and SUZHOU, China, May 20, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Company's Executive Director and Chief Medical O...
2022-05-20 12:31
2905
Clinical trial results of Belief BioMed's hemophilia B gene therapy drug candidate BBM-H901 published in The Lancet Haematology
SHANGHAI, May 20, 2022 /PRNewswire/ -- The early phase clinical trial results of BBM-H901, the first intravenously injectable hemophilia B gene therapy product developed and tested inAsia, are published in The Lancet Haematology, a top international journal in hematology. https://www.thelancet....
2022-05-20 10:43
3870
CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing
TIANJIN, China, May 19, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that the World Health Organization ("WHO") has granted Emergency Use Listing ("EUL") for Convidecia™, CanSinoBIO's Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5...
2022-05-19 23:28
3478
All Border Ports in Guangxi Commenced Normal Operations
NANNING, China, May 19, 2022 /PRNewswire/ -- Statistics from the Department of Commerce of Guangxi Zhuang Autonomous Region show that during the May Day holiday in 2022, a total of 3,344 vehicles entered and exited throughGuangxi border highway ports, including 1,601 and 1,743 vehicles leaving an...
2022-05-19 21:39
2414
Lunit AI Biomarker PD-L1 Demonstrates Clinical Efficacy as Diagnostic Aid in Cancer Treatment-Published in the European Journal of Cancer
* Study findings show that Lunit's AI-powered PD-L1 TPS analyzer minimizes interpretation discrepancy among pathologists * AI-assisted PD-L1 TPS reading using Lunit SCOPE PD-L1 leads to better prediction of therapeutic outcomes in non-small cell lung cancer patients * In April 2022, Lunit SC...
2022-05-19 21:00
1210
CellCarta expands it proteomics portfolio with the acquisition of next-generation immuno-MRM assays from Precision Assays
This acquisition solidifies CellCarta's leadership position in proteomics serviceswith a unique combination of validated set of reagents and multiplex assays, including pathway specific off-the-shelf panels, allowing for clinical protein quantification covering a comprehensive range of immuno-onc...
2022-05-19 20:30
1621
4C Medical Technologies Presents Data from the Global Clinical Experience for the AltaValve Early Feasibility Study at AATS 2022
MINNEAPOLIS, May 19, 2022 /PRNewswire/ -- 4C Medical Technologies, Inc. ("4C Medical" or the "Company"), a privately-held medical technology company focused on the development of minimally invasive therapies for structural heart disease, presented its global clinical experience from its initial A...
2022-05-19 20:06
2140
Berry Oncology Launches an Innovative Self-Iterative "HIFI" System
BEIJING, May 18, 2022 /PRNewswire/ -- Berry Oncology, a leading company in the global industry for genetic testing and early screening of tumors, recently launched a HIFI system. The HIFI system consists of HIFI-det liquid biopsy technology and the corresponding HIFI-cal series of algorithms. W...
2022-05-19 09:00
2379
FSP, the Top Brand of Power Supply in Five Application Fields
-Edge Computing/Medical/Smart Energy/Gaming/PD Charger- TAIPEI, May 19, 2022 /PRNewswire/ -- FSP Group, the world's leading high-performance ODM & Modified STD power supply manufacturer, today unveils the next wave of products designed with bleeding-edge technology that outperforms their rivals....
2022-05-19 08:30
3079
PostEra spearheads AI-driven drug discovery collaboration to develop antiviral therapeutics with initial $68M in NIH funding
BOSTON, May 19, 2022 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced a multi-year collaboration with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics. The cente...
2022-05-19 04:56
2640
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
VANCOUVER, BC, May 18, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that Hospices Civils deLyon, France ("HCL") has agreed to serve as a clinical study site for the Phase I study of BVX-0918, the Company's autologous ...
2022-05-18 20:00
3888
DelSiTech and Anticancer Bioscience Announce a Collaboration Agreement for the Development of Long-acting Therapies in Oncology
TURKU, Finland, May 18, 2022 /PRNewswire/ -- DelSiTech Ltd, the leading silica drug delivery technology company, based inFinland and Anticancer Bioscience Ltd., an innovativeChina-base and international company pioneers in synthetic lethal approaches to precision oncology, today announced a notab...
2022-05-18 16:00
1984
Antengene Announces XPOVIO® Treatment Regimens Included for the First Time in the Guidelines for the Diagnosis and Management of Multiple Myeloma in China
SHANGHAI and HONG KONG, May 18, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...
2022-05-18 15:01
2607
SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China
HONG KONG, May 18, 2022 /PRNewswire/ -- SIMCERE PHARMA (HK.2096) announced that SIM0417, a candidate drug against SARS-Cov-2, for which the Company holds license from Shanghai Institute ofMateria Medica (SIMM) and Wuhan Institute of Virology, Chinese Academy of Sciences, has obtained the Clinica...
2022-05-18 11:56
2021
Sinclair Pharma Partners with Vanguard Aesthetics to Launch Silhouette Soft in Malaysia
Equipped with the world's only cone technology for optimal lift, Silhouette
Soft provides longer lasting results.
KUALA LUMPUR, Malaysia, May 18, 2022 /PRNewswire/ -- Sinclair Pharma
2022-05-18 09:01
2570
P&G Health dons the Purple Ribbon to commemorate Neuropathy Awareness Week
* Launches 'Feel Life' campaign in 18 countries across Asia Pacific, Middle East, India, and Africa to raise awareness on Peripheral Neuropathy * Global Webinar Series for healthcare professionals with 'Virtual Pavilions' representing Peripheral neuropathy issues in each country, along with be...
2022-05-17 19:24
2106
ASEAN accepts mutually recognized COVID-19 vaccination certificates
DENPASAR, Indonesia, May 17, 2022 /PRNewswire/ -- ASEAN Member States collectively recognize the COVID-19 vaccination certificate to be applied in Southeast Asia. Health Ministers of ASEAN countries endorsed the decision during the 15th ASEAN Health Ministers Meeting (15th AHMM) inNusa Dua, Bali, ...
2022-05-17 19:14
2008
New therapeutic option to reduce risk of cardiovascular deaths and repeated hospitalizations among adult heart failure patients approved in Singapore
* Over the course of the VICTORIA study, there was a 4.2% reduction in annualized absolute risk with VERQUVO™ (vericiguat) compared with placebo in reducing the risk of cardiovascular death or heart failure (HF) hospitalization in adults with symptomatic chronic HF and ejection fraction less th...
2022-05-17 16:32
1742
ABL AND ODIMMA THERAPEUTICS JOIN FORCES IN PERSONALIZED CANCER IMMUNOTHERAPY
PARIS, May 17, 2022 /PRNewswire/ -- ABL Europe (ABL
2022-05-17 15:00
2080
CStone announces final PFS analysis of a registrational study of sugemalimab in patients with stage III NSCLC further demonstrates its robust efficacy and significant clinical benefits shown in interim analysis
* Sugemalimab is the world's first anti-PD-(L)1 monoclonal antibody to significantly improve progression-free survival (PFS) in patients with stage III non-small cell lung cancer (NSCLC) without disease progression following concurrent or sequential chemoradiotherapy * The National Medical Pr...
2022-05-17 08:02
2707
Week's Top Stories
Most Reposted
k-ID Closes $45 Million Series A from Andreessen Horowitz and Lightspeed Venture Partners to Set a New Global Benchmark for Age-appropriate Gaming Experiences
[Picked up by 320 media titles]
2024-06-25 21:00
10 Start-ups Awarded in HK Tech 300 Southeast Asia Start-up Competition Fostering Innovation & Entrepreneurship Beyond Boundaries
[Picked up by 316 media titles]
2024-06-27 18:56
Labuan IBFC Inc. and STEP Malaysia jointly host wealth management and estate planning event
[Picked up by 314 media titles]
2024-06-28 12:45
Born Global, Connecting the World - C&D Inc. Debuts at the "The 1st Global Summit of Chinese Enterprises Going Overseas and 2024 Mid-Year Industry Summit"
[Picked up by 297 media titles]
2024-06-23 13:50
SCO strengthening youth development for better future
[Picked up by 297 media titles]
2024-06-24 10:52
Most Read
Lilyannie Christie Linus Crowned Miss Grand Malaysia Sabah 2024
2024-06-25 13:38
10824
Born Global, Connecting the World - C&D Inc. Debuts at the "The 1st Global Summit of Chinese Enterprises Going Overseas and 2024 Mid-Year Industry Summit"
2024-06-23 13:50
7728
k-ID Closes $45 Million Series A from Andreessen Horowitz and Lightspeed Venture Partners to Set a New Global Benchmark for Age-appropriate Gaming Experiences
2024-06-25 21:00
7233
SCO strengthening youth development for better future
2024-06-24 10:52
6673